Profil
James E.
Audia is currently the Director at Ribon Therapeutics, Inc. and a Member at Alzheimer's Association.
Previously, he served as the Independent Director at Constellation Pharmaceuticals, Inc. from 2011 to 2021.
He was also the Executive Director at Chicago Biomedical Consortium from 2017 to 2019.
Additionally, he held the position of Head-Chemistry at Karuna Therapeutics, Inc. from 2019 to 2024.
Dr. Audia obtained his doctorate degree from Yale University and the University of South Carolina.
Postes actifs de James E. Audia
| Sociétés | Poste | Début |
|---|---|---|
Ribon Therapeutics, Inc.
Ribon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops cacner therapies | Directeur/Membre du Conseil | 01/04/2018 |
Alzheimer’s Association
Alzheimer’s Association Miscellaneous Commercial ServicesCommercial Services Noncommercial Research Organizations | Corporate Officer/Principal | 01/01/2020 |
Anciens postes connus de James E. Audia
| Sociétés | Poste | Fin |
|---|---|---|
| KARA THER | Corporate Officer/Principal | 18/03/2024 |
| CONSTELLATION PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/07/2017 |
Chicago Biomedical Consortium | Directeur/Membre du Conseil | 01/10/2019 |
Formation de James E. Audia
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of South Carolina
University of South Carolina Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alzheimer’s Association
Alzheimer’s Association Miscellaneous Commercial ServicesCommercial Services Noncommercial Research Organizations | Commercial Services |
Constellation Pharmaceuticals, Inc.
Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs targeting regulators of epigenetic function | Health Technology |
Karuna Therapeutics, Inc.
Karuna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops medicines for psychiatric and neurological disorders like schizophrenia and Alzheimer’s disease | Health Technology |
Ribon Therapeutics, Inc.
Ribon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops cacner therapies | Health Technology |
Chicago Biomedical Consortium |
















